Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $38.8 million.

  • Bolt Biotherapeutics' Cash & Equivalents rose 31426.44% to $38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year increase of 31426.44%. This contributed to the annual value of $7.2 million for FY2024, which is 3334.88% down from last year.
  • Latest data reveals that Bolt Biotherapeutics reported Cash & Equivalents of $38.8 million as of Q3 2025, which was up 31426.44% from $48.5 million recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year Cash & Equivalents high stood at $95.5 million for Q1 2021, and its period low was $4.3 million during Q1 2024.
  • For the 5-year period, Bolt Biotherapeutics' Cash & Equivalents averaged around $26.9 million, with its median value being $14.8 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 7127.26% in 2024, then soared by 126086.34% in 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Cash & Equivalents (Quarter) stood at $27.4 million in 2021, then crashed by 66.24% to $9.2 million in 2022, then grew by 16.94% to $10.8 million in 2023, then plummeted by 33.35% to $7.2 million in 2024, then surged by 438.51% to $38.8 million in 2025.
  • Its Cash & Equivalents stands at $38.8 million for Q3 2025, versus $48.5 million for Q2 2025 and $58.0 million for Q1 2025.